

Annexure



Figure 2: Factors affecting policy design.

Policy Designs • Problems and Goals • Rationales and Assumptions Targets • Rules and Tools Agents / • Implementation Structures **Designing Dynamics Translation Dynamics** · (Re)framing Issues Experiences Setting Agendas Messages, Interpretations, Calculating Opportunities & Risks Exercising Leadership Lessons · Conceptions of Government Analyzing Policies and Role of Citizens Deconstructing Designs, Copying Participation Patterns or Creating Designs **Societal Context** Issue Context Framing Dynamics Interpretations of: Cit izenship. Social Constructions Events Democratic Values Political Power: Type's and GroupsKnowledge Distributions Justice Institutions and institutional Proble m-Solving Societal Conditions Attitudes Toward Government Culture:

Source: Schneider and Larson. 1997. [1]



Table 1: Country scores on robustness of decision-making.

High to low pneumococcal		Robustness of Policies & Decision-Making													
vaccine coverage	Early or Late Adopter	Manufacturer requirements	Surveillance	Health Security driven	C-E driven	NITAG- working groups	PCV policy	HZV policy	Nat'l Aging Strategy	Nat'l Immunization Strategy	R A N K	SCORE			
UK	2	1	2	1	2	2	1	2	1.5	2	2	16.5			
US	2	2	2	1	1	2	2	2	1	2	1	17			
Mexico	2	2	1	2	1	0	0	0	2	2	9	12			
Korea	2	2	2	0	1	1	0	2	1	0	12	11			
Colombia	0	2	1	1	1	1	1	0	1	2	15	10			
Australia	1	2	2	2	1	2	1.5	2	1	2	2	16.5			
Spain	2	2	1	1	1	0	1	0	1	0	17	9			
Canada	1	2	1	1	1	2	2	2	1	2	5	15			
Ireland	1	2	1	0	1	0	2	0	1	0	19	8			
Germany	2	1	2	1	1	2	2	2	1	0	7	14			
Belgium	2	1	1	0	1	1	2	1	2	0	12	11			
Taiwan	2	2	1	2	1	0	0	0	0	0	20	8			
Japan	0	1	1	2	1	0	0	1	1	0	23	7			
Norway	1	2	1	0	1	0	0	2	1	0	20	8			
UAE	1	0	1	1	0	0	1	2	0	2	20	8			
Argentina	1	1	1	2	0	2	2	0	2	0	12	11			
Saudi Arabia	1	0	1	2	0	0	0	0	0	0	29	4			
Italy	2	2	1	2	1	0	2	2	2	2	4	16			
China	0	0	1	2	1	0	0	0	1	0	27	5			
Turkey	1	2	1	2	1	0	0	0	1	1	17	9			
Brazil	0	0	1	1	1	1	2	0	2	2	15	10			
Denmark	1	2	1	0	0	0	0	0	0	0	29	4			
France	1	2	1	1	1	2	2	2	1	0	8	13			
Greece	2	2	1	2	0	0	0	0	0	0	23	7			
Hong Kong	1	0	1	2	1	0	2	0	0	0	23	7			
India	0	1	1	1	0	0	0	0	1	0	14	4			
Malaysia	0	2	1	1	1	0.5	2	0	1	0	19	8.5			
New Zealand	1	2	2	2	0	0	1	1	1	2	9	12			
Peru	0	2	1	0	0	0	0	0	1	0	29	4			
Philippines	0	1	1	1	0	0	0	0	1	0	29	4			
Russia	0	1	1	1	1	0	0	0	1	0	27	5			
Sweden	2	2	1	1	2	0	2	2	0	0	9	12			
Switzerland	0	2	1	1	0	0	0	0	0	0	29	4			
Netherlands	2	1	2	0	1.5	2	1.5	1.5	1	2	6	14.5			
	scoring	: 2		1.5		1		0.5		0					

Source: Privor- Dumm et al. 2020. [2]



Table 2: Country scores on program implementation.

High to low	Promotion of Implementation & Uptake															
pneumococcal vaccine coverage	Publi	Public Financing for Vaccines			Vaccine Registry		ilabili		Advocacy	Influence of	Access	Equity focus	Degree of Centralization Adult Health		Rank	Score
	Influenza	Pneumococcal	Herpes Zoster	Adult	Pediatric	influenza	Pneumococcal	Herpes Zoster		champions			Vaccine Delivery	Health System Delivery	a.	
UK	2	2	2	2	2	2	2	2	1	0	2	0	2	2	1	23
US	1.5	1.5	1.5	1	1	2	2	2	2	1	2	1	1	1	4	20.5
Mexico	2	2	0	1	1	1	1	0	1	1	1	1	1	1	10	14
Korea	2	0	0	2	2	2	2	2	2	1	2	0	1	1	5	19
Colombia	2	1	0	2	2	1	1	0	1	1	1	0	2	0	10	14
Australia	2	1	2	2	2	1	1	1	2	1	2	2	1	1	3	21
Spain	2	1	1	0	2	1	1	0	1	1	0	0	1	2	14	13
Canada	2	2	1	1	1	2	2	1	2	2	1	1	1	0	5	19
Ireland	2	0	0	1	1	2	2	0	1	1	2	0	0	2	10	14
Germany	2	2	0	1	2	2	1	0	0	1	0	0	1	0	17	12
Belgium	1	1	0	1	1	1	1	0	1	1	1	0	2	1	17	12
Taiwan	2	0	0	0	1	1	1	0	1	1	0	0	1	1	23	9
Japan	2	1	0	0	2	0	1	0	1	1	1	0	0	0	23	9
Norway	2	1	0	2	2	1	1	0	1	1	0	1	2	2	8	16
UAE	2	2	2	2	2	0	1	0	0	1	1	0	2	0	9	15
Argentina	2	0	0	0	1	1	1	0	1	2	1	1	2	0	17	12
Saudi Arabia	2	0	0	0	2	0	0	0	0	0	1	0	0	2	28	7
Italy	2	2	2	1	1	2	1	1	1	1	0	2	1	1	7	18
China	1	1	0	0	1	1	1	0	1	1	1	0	1	2	20	11
Turkey	2	2	0	0	0	1	1	0	1	1	1	0	0	0	23	9
Brazil	2	1	0	1	2	2	0	0	1	2	1	1	1	0	10	14
Denmark	2	0	0	2	2	1	0	0	1	1	0	0	2	2	14	13
France	2	1	0	0	0	1	0	0	1	1	1	0	0	0	28	7
Greece	2	2	0	0	0	0	0	0	1	1	0	1	0	0	28	7
Hong Kong	2	2	0	0	1	1	0	0	1	1	2	0	0	0	21	10
India	0	0	0	0	0	1	0	0	1	1	1	0	1	0	32	5
Malaysia	0	0	0	0	1	1	0	0	1	1	0	0	2	2	27	8
New Zealand	2	2	2	2	2	2	0	0	2	1	2	2	1	2	2	22
Peru	0	0	0	0	1	0	0	0	1	1	1	0	0	0	33	4
Philippines	2	2	0	0	2	1	0	0	1	1	1	0	0	0	21	10
Russia	0	0	0	0	0	1	0	0	0	0	1	0	1	1	33	4
Sweden	1	1	0	0	2	1	0	0	1	1	2	0	0	0	23	9
Switzerland	1	0	0	0	2	1	0	0	1	1	1	0	0	0	28	7
Netherlands	2	0	0	1	2	1	0	0	1	1	2	0	2	1	14	13
		scori	ng:		2			1.5		1	0	.5		0		


 Table 3: Link between funding and influenza vaccination
 coverage in 30 EU/EEA countries.

Country	Coverage rate in funded countries (N=24)	Average coverage rate in non-funded countries (N=4)
Average	44%	12%
Austria		18%
Belgium	59%	
Bulgaria		4%
Croatia	29%	
Cyprus	26%	
Czech	23%	
Denmark	52%	
Estonia		15%
Finland	47%	
France	52%	
Germany	39%	
Greece	74%	
Hungary	24%	
Iceland	55%	
Ireland	71%	
Italy	55%	
Latvia	12%	
Lichtenstein	20%	
Luxembourg	40%	
Malta	53%	
Netherlands	61%	
Norway	57%	
Poland		10%
Portugal	61%	
Slovakia	12%	
Slovenia	19%	
Spain	66%	
Sweden	53%	

Source: Privor-Dumm et al. 2020 [2] Sources: Eurostat [3] & OECD [4]




Figure 2: Total government expenditure on health as a percentage of GDP, EU/EA, 2019.



Sources: Eurostat. 2021. [5]




Figure 3: Maximal vaccination cost throughout life in Germany.




Source: Ethgen et al. 2016. [6]

Figure 5: Maximal vaccination cost throughout life in France.




Source: Ethgen et al. 2016. [6]

Figure 4: Maximal vaccination cost throughout life in England.



Source: Ethgen et al. 2016. [6]


Figure 6: Maximal vaccination cost throughout life in Italy.



Source: Ethgen et al. 2016. [6]




Figure 7: Maximal vaccination cost throughout life in Spain.




Source: Ethgen et al. 2016. [6]

Figure 8: Maximal vaccination cost throughout life in Sweden.



Source: Ethgen et al. 2016. [6]

Figure 9: Maximal vaccination cost throughout life in Portugal.



Source: Ethgen et al. 2016. [6]

References

- 1. Schneider, Anne Larason and Helen Ingram. 1997. Policy Design for Democracy. Lawrence, Kansas: University Press of Kansas, page 74. https://catalogue.nla.gov.au/Record/1623565
- 2. Privor-Dumm, Lois A., Gregory A. Poland, Jane Barratt, David N. Durrheim, Maria Deloria Knoll, Prarthana Vasudevan, Mark Jit, Pablo E. Bonvehí, Paolo Bonanni, and International Council on Adult Immunization. "A Global Agenda for Older Adult Immunization in the COVID-19 Era: A Roadmap for Action." Vaccine 39, no. 37 (August 31, 2021): 5240-50. https://doi.org/10.1016/i.vaccine.2020.06.082
- Statistics | Eurostat." Accessed January 7, 2022. https://ec.europa.eu/eurostat/databrowser/ view/hlth_ps_immu/default/table?lang=en
- 4. The OECD. "Health Care Use Influenza Vaccination Rates OECD Data." Accessed January 7, 2022. http://data.oecd.org/healthcare/influenza-vaccination-rates.htm
- 5. Eurostat. Total general government expenditure on health, 2019 (% of GDP) https://ec.europa.eu/eurostat/statistics-explained/index.php?title=File:Total_general_government_expenditure_on_health,_2019_(%25_of_GDP).png
- 6. Ethgen, Olivier, Murielle Cornier, Emilie Chriv, and Florence Baron-Papillon. 2016. "The Cost of Vaccination throughout Life: A Western European Overview." Human Vaccines and Immunotherapeutics 12 (8): 2029-37. https://doi.org/10.1080/21645515.2016.1154649





The International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) represents over 90 innovative pharmaceutical companies and associations around the world. Our industry's almost three million employees discover, develop, and deliver medicines and vaccines that advance global health. Based in Geneva, IFPMA has official relations with the United Nations and contributes industry expertise to help the global health community improve the lives of people everywhere.